November 01, 2021

Accenture Positioned as a Leader in IDC MarketScape: Worldwide Life Sciences Research & Development Vendor Assessment on IT Outsourcing for Fourth Consecutive Report


NEW YORK; Nov. 1, 2021 – For the fourth consecutive time, Accenture (NYSE: ACN) is positioned as a Leader in the IDC MarketScape vendor assessment covering IT outsourcing (ITO) across the life sciences research and development (R&D) industry.

The report, “IDC MarketScape: Worldwide Life Science R&D ITO Services 2021 Vendor Assessment” examines the current life sciences R&D ITO landscape, including industry and market trends, and compares 11 major vendors against criteria IDC views as most important for life sciences companies to consider when selecting a service provider.

The report recognizes Accenture’s expertise in “building agile, lean, and digitally enabled business models from early discovery through approval, launch, delivery, full commercialization, and patient services.”

The report also notes that INTIENT, Accenture’s Life Sciences cloud platform for the enablement of intelligent business processes in the discovery, development and commercialization of New Science, is key to delivering leading R&D ITO services, such as clinical trial operations.

“Accenture leverages new tech, such as AI, machine learning, robotic process automation, and advanced analytics and has strong relationships with cloud providers, as well as enterprise software leaders and niche players, which makes it a very strong service provider,” said Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC. “As a result, Accenture has helped 90% of Fortune 500 Life Science companies deliver improved outcomes to patients, which clearly makes it stand out as a leader.”

“Technology has moved from an enabler to a core and central element of life sciences research and development. We are working with our clients to define technology-enabled business strategies, implement new technology platforms, and provide scaled operations in multi-year arrangements,” said Tom Lehmann, who leads Life Sciences R&D at Accenture. “Our global team is focused on using technology to reshape and deliver the R&D essential to delivering new products and treatments to patients.”

An excerpt of the “IDC MarketScape: Worldwide Life Science R&D ITO Services 2021 Vendor Assessment” is available here.

Accenture also was positioned as a Leader for the fourth consecutive time in two more recent reports from IDC:

Accenture’s Life Sciences industry group helps pharmaceutical, biotech, medical technology, distributor and consumer health companies combine the latest technology with scientific breakthroughs to revolutionize how medical treatments are discovered, developed and delivered to patients around the world. To learn more, visit https://www.accenture.com/us-en/industries/life-sciences-index.

About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 624,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

# # #

Contact:

Marchell Gillis
Accenture
+1 678 657 7515 (office)
+1 404 409 9430 (mobile)
marchell.gillis@accenture.com

Copyright ©2021 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.